There are many areas in thoracic oncology with open questions that need answers. Between them indications for surgery for advanced lung and esophageal cancer remain uncertain. The recent report on operable N2 disease in lung cancer has as a result that more questions have arisen. The surgeon has to reconsider the best strategy for lymphadenectomy for example. Moreover the reasonable results have been obtained for selected M1a lung cancer with pleurectomy/decortication and HITHOC alert us to expanding indications and the possible necessity of a individualized surgery. The use of VATS in locally advanced lung and esophageal cancer could be feasible in expert hands but are not for every surgeon yet. Hope but not false hope should be given to patients with recurrent disease after esophagectomy especially for those with limited recurrence (solitary locoregional recurrence or solid organ metastasis). We believe that advanced lung and esophageal cancer does not always mean the end.
Residents and medical students are encouraged to send their abstracts of no more than 250 words as follows: introduction, AIM, Methods, Results, Conclusions.
To the Authors of the best abstracts it will be asked in advance to write the full paper for proposal of publication in Future Oncology.
University of Catania

Sponsor
BAXTER
For scientific informations email to:
mmiglior@unict.it
Provider ECM nr.4842 and congress organizer FULLCONGRESS Email: info@fullcongress.it Phone: 39 -339 2424474 (Daniela La Russa) Congress fee: surgeons 150, residents 70, medical students free
